A Study Evaluation the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in Patients With Primary Hypothyroidism
Phase 2
Active, not recruiting
- Conditions
- Hypothyroidism
- Interventions
- Drug: North Star
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Neuvosyn Laboratories, LLC
- Target Recruit Count
- 300
- Registration Number
- NCT05712421
- Locations
- 🇺🇸
Neuvosyn Investigational Site, Stafford, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath